Trial Profile

A Phase II Study of Cabozantinib (XL184) Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 09 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

03 Jun 2022 Status changed from active, no longer recruiting to discontinued as PI left institution.
01 Feb 2022 Planned End Date changed from 31 Dec 2021 to 16 Feb 2022.
01 Feb 2022 Planned primary completion date changed from 31 Dec 2021 to 16 Feb 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com